DRUG
Bright Minds Biosciences Inc.
Biotechnology
Market Cap$864M
5Y Perf.+232.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
DRUG vs MNMD
Revenue, margins, valuation, and 5-year total return — side by side.
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.-54.8%
DRUG vs MNMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | DRUG | MNMD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $864M | $2.04B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-11M | $-238M |
| Total Debt | $126K | $0.00 |
| Cash & Equiv. | $83M | $258M |
DRUG vs MNMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DRUG
MNMD
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Bright Minds Biosci… (DRUG) | 100 | 332.0 | +232.0% |
| Mind Medicine (Mind… (MNMD) | 100 | 45.2 | -54.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DRUG vs MNMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNMD leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Bright Minds Biosciences Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
DRUG
Bright Minds Biosciences Inc.
The Growth Play
DRUG is the clearest fit if your priority is growth exposure.
- EPS growth -96.9%
- 1.3% margin vs MNMD's 1.2%
- -13.1% ROA vs MNMD's -70.7%
Best for: growth exposure
MNMD
Mind Medicine (MindMed) Inc.
The Income Pick
MNMD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.68
- 5.1% 10Y total return vs DRUG's 228.9%
- Lower volatility, beta 1.68, current ratio 6.29x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MNMD | -96.9% revenue growth vs DRUG's -305.3% |
| Quality / Margins | DRUG | 1.3% margin vs MNMD's 1.2% |
| Stability / Safety | MNMD | Beta 1.68 vs DRUG's 1.87 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MNMD | +214.0% vs DRUG's +195.1% |
| Efficiency (ROA) | DRUG | -13.1% ROA vs MNMD's -70.7% |
DRUG vs MNMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDRUGLAGGINGMNMD
MNMDMind Medicine (MindMe…
1leads
DRUGBright Minds Bioscien…
2leads
6 Total Categories
CATEGORYLEADERvs MNMDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DRUG1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DRUG4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
MNMD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DRUG leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
DRUG and MNMD operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | DRUGBright Minds Bios… | MNMDMind Medicine (Mi… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$12M | -$191M |
| Net IncomeAfter-tax profit | -$11M | -$238M |
| Free Cash FlowCash after capex | -$8M | -$174M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -141.2% | -163.0% |
DRUG leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — DRUG and MNMD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | DRUGBright Minds Bios… | MNMDMind Medicine (Mi… |
|---|---|---|
| Market CapShares × price | $864M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $804M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -94.67x | -10.04x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 10.16x | 5.56x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — DRUG and MNMD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
DRUG leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
DRUG delivers a -13.5% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-102 for MNMD. On the Piotroski fundamental quality scale (0–9), DRUG scores 4/9 vs MNMD's 3/9, reflecting mixed financial health.
| Metric | DRUGBright Minds Bios… | MNMDMind Medicine (Mi… |
|---|---|---|
| ROE (TTM)Return on equity | -13.5% | -102.5% |
| ROA (TTM)Return on assets | -13.1% | -70.7% |
| ROICReturn on invested capital | — | -3.9% |
| ROCEReturn on capital employed | -31.8% | -52.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.00x | — |
| Net DebtTotal debt minus cash | -$83M | -$258M |
| Cash & Equiv.Liquid assets | $83M | $258M |
| Total DebtShort + long-term debt | $125,777 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -541.45x | -21.81x |
DRUG leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — DRUG and MNMD each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DRUG five years ago would be worth $38,216 today (with dividends reinvested), compared to $4,205 for MNMD. Over the past 12 months, MNMD leads with a +214.0% total return vs DRUG's +195.1%. The 3-year compound annual growth rate (CAGR) favors DRUG at 2.1% vs MNMD's 82.7% — a key indicator of consistent wealth creation.
| Metric | DRUGBright Minds Bios… | MNMDMind Medicine (Mi… |
|---|---|---|
| YTD ReturnYear-to-date | +6.4% | +51.7% |
| 1-Year ReturnPast 12 months | +195.1% | +214.0% |
| 3-Year ReturnCumulative with dividends | +2860.5% | +510.3% |
| 5-Year ReturnCumulative with dividends | +282.2% | -57.9% |
| 10-Year ReturnCumulative with dividends | +228.9% | +512.1% |
| CAGR (3Y)Annualised 3-year return | +2.1% | +82.7% |
Evenly matched — DRUG and MNMD each lead in 3 of 6 comparable metrics.
Risk & Volatility
MNMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MNMD is the less volatile stock with a 1.68 beta — it tends to amplify market swings less than DRUG's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs DRUG's 71.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DRUGBright Minds Bios… | MNMDMind Medicine (Mi… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.87x | 1.68x |
| 52-Week HighHighest price in past year | $123.75 | $21.09 |
| 52-Week LowLowest price in past year | $23.18 | $6.03 |
| % of 52W HighCurrent price vs 52-week peak | +71.8% | +98.1% |
| RSI (14)Momentum oscillator 0–100 | 57.6 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 156K | 792K |
MNMD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates DRUG as "Buy" and MNMD as "Buy". Consensus price targets imply 53.7% upside for DRUG (target: $137) vs -3.3% for MNMD (target: $20).
| Metric | DRUGBright Minds Bios… | MNMDMind Medicine (Mi… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $136.50 | $20.00 |
| # AnalystsCovering analysts | 3 | 1 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DRUG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MNMD leads in 1 (Risk & Volatility). 2 tied.
Best OverallBright Minds Biosciences In… (DRUG)Leads 2 of 6 categories
Loading custom metrics...
DRUG vs MNMD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DRUG or MNMD a better buy right now?
Analysts rate Bright Minds Biosciences Inc.
(DRUG) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DRUG or MNMD?
Over the past 5 years, Bright Minds Biosciences Inc.
(DRUG) delivered a total return of +282. 2%, compared to -57. 9% for Mind Medicine (MindMed) Inc. (MNMD). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus DRUG's +228. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DRUG or MNMD?
By beta (market sensitivity over 5 years), Mind Medicine (MindMed) Inc.
(MNMD) is the lower-risk stock at 1. 68β versus Bright Minds Biosciences Inc. 's 1. 87β — meaning DRUG is approximately 11% more volatile than MNMD relative to the S&P 500.
04Which is growing faster — DRUG or MNMD?
On earnings-per-share growth, the picture is similar: Bright Minds Biosciences Inc.
grew EPS -96. 9% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DRUG or MNMD?
Bright Minds Biosciences Inc.
(DRUG) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Mind Medicine (MindMed) Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DRUG leads at 0. 0% versus 0. 0% for MNMD. At the gross margin level — before operating expenses — DRUG leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DRUG or MNMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DRUG or MNMD better for a retirement portfolio?
For long-horizon retirement investors, Mind Medicine (MindMed) Inc.
(MNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+512. 1% 10Y return). Bright Minds Biosciences Inc. (DRUG) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNMD: +512. 1%, DRUG: +228. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DRUG and MNMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.